[Infections in stem cell transplantation].
The morbidity and mortality associated with infections in stem cell transplantation (SCT) has decreased considerably in recent years because of increasing knowledge of related risk factors, immune recovery, and the pattern of infection according to the phase of evolution of SCT, and the introduction of new and more effective antimicrobial agents. These advances, together with the use of peripheral blood stem cells, T-lymphoid cell depletion, stimulating factors, and more potent immunosuppressors has reduced SCT mortality and broadened the indications for this treatment. Nevertheless, infection continues to a prominent complication in these patients.
Rovira
Montserrat
M
Unidad de Trasplantament, Servicio Hematología, Hospital Clínic, Barcelona, España.
Camps
Isabel Ruiz
IR
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001424:Bacterial Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008212:Lymphocyte Depletion / Q000009:adverse effects; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications / Q000209:etiology; D009894:Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D011292:Premedication; D012307:Risk Factors; D014123:Toxoplasmosis / Q000453:epidemiology / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014777:Virus Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents